Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 324

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

A Controlled Trial of Early versus Late Treatment with Zidovudine in Symptomatic Human Immunodeficiency Virus Infection

Open access
Hamilton, John D., Hartigan, Pamela M., Simberkoff, Michael S., Day, Philip L., Diamond, Gigi R., Dickinson, Gordon M., Drusano, George L., Egorin, Merrill J., George, W. Lance, Gordin, Fred M., Hawkes, Clifton A., Jensen, Peter C., Klimas, Nancy G., Labriola, Ann M., Lahart, Christopher J., O'Brien, William A., Oster, Charles N., Weinhold, Kent J., Wray, Nelda P., Zolla-Pazner, Susan B.·1992·New England Journal of Medicine

Abstract

BACKGROUND: Zidovudine is recommended for asymptomatic and early symptomatic human immunodeficiency virus (HIV) infection. The best time to initiate zidovudine treatment remains uncertain, however, and whether early treatment improves survival has not been established. METHODS: We conducted a multicenter, randomized, double-blind trial that compared early zidovudine therapy (beginning at 1500 mg per day) with late therapy in HIV-infected patients who were symptomatic and had CD4+ counts between 0.2 x 10(9) and 0.5 x 10(9) cells per liter (200 to 500 per cubic millimeter) at entry. Those assigned to late therapy initially received placebo and began zidovudine when their CD4+ counts fell below 0.2 x 10(9) per liter (200 per cubic millimeter) or when the acquired immunodeficiency syndrome (AIDS) developed. RESULTS: During a mean follow-up period of more than two years, there were 23 deaths in the early-therapy group (n = 170) and 20 deaths in the late-therapy group (n = 168) (P = 0.48; relative risk [late vs. early], 0.81; 95 percent confidence interval, 0.44 to 1.59). In the early-therapy group, 28 patients progressed to AIDS, as compared with 48 in the late-therapy group (P = 0.02; relative risk, 1.76; 95 percent confidence interval, 1.1 to 2.8). Early therapy increased the time until CD4+ counts fell below 0.2 x 10(9) per liter (200 per cubic millimeter), and it produced more conversions from positive to negative for serum p24 antigen. Early therapy was associated with more anemia, leukopenia, nausea, vomiting, and diarrhea, whereas late therapy was associated with more skin rash. CONCLUSIONS: In symptomatic patients with HIV infection, early treatment with zidovudine delays progression to AIDS, but in this controlled study it did not improve survival, and it was associated with more side effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199202133260703

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 324

Metadata

Authors
Hamilton, J. D., Hartigan, P. M., Simberkoff, M. S., Day, P. L., Diamond, G. R., Dickinson, G. M., Drusano, G. L., Egorin, M. J., George, W. L., Gordin, F. M., Hawkes, C. A., Jensen, P. C., Klimas, N. G., Labriola, A. M., Lahart, C. J., O'Brien, W. A., Oster, C. N., Weinhold, K. J., Wray, N. P., & Zolla-Pazner, S. B.
Venue
New England Journal of Medicine
Published
1992-02-13
Volume
326
Issue
7
Pages
437-443
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2319972101
Cited by
324
References
15
FWCI
52.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Controlled Trial of Early versus Late Treatment with Zidovudine in Symptomatic Human Immunodeficiency Virus Infection. https://app.cochat.ai/papers/10.1056/nejm199202133260703
The paper
Hamilton, J. D., Hartigan, P. M., Simberkoff, M. S., Day, P. L., Diamond, G. R., Dickinson, G. M., Drusano, G. L., Egorin, M. J., George, W. L., Gordin, F. M., Hawkes, C. A., Jensen, P. C., Klimas, N. G., Labriola, A. M., Lahart, C. J., O'Brien, W. A., Oster, C. N., Weinhold, K. J., Wray, N. P., & Zolla-Pazner, S. B. (1992). A Controlled Trial of Early versus Late Treatment with Zidovudine in Symptomatic Human Immunodeficiency Virus Infection. New England Journal of Medicine. https://doi.org/10.1056/nejm199202133260703

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.